Sonnet Biotherapeutics Holdings Inc (SONN) — Cash Flow-to-Debt Ratio
Sonnet Biotherapeutics Holdings Inc (SONN) has a Cash Flow-to-Debt Ratio of -0.34x as of June 2025, meaning its operating cash flow of $-1.76 Million could theoretically repay 0% of its total liabilities ($5.10 Million) in one year. See SONN FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sonnet Biotherapeutics Holdings Inc Cash Flow-to-Debt Ratio (2009–2025)
Historical debt coverage capacity for Sonnet Biotherapeutics Holdings Inc across 15 annual periods. Also explore SONN net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Sonnet Biotherapeutics Holdings Inc (2009–2025)
Year-by-year debt coverage analysis for Sonnet Biotherapeutics Holdings Inc. For market capitalisation and broader financial context, see Sonnet Biotherapeutics Holdings Inc (SONN) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.13x | $-12.83 Million | $4.10 Million | ▼ -18.5% |
| 2024 | -2.64x | $-8.61 Million | $3.26 Million | ▲ +30.0% |
| 2023 | -3.77x | $-21.34 Million | $5.66 Million | ▼ -14.1% |
| 2022 | -3.31x | $-27.69 Million | $8.37 Million | ▲ +1.2% |
| 2021 | -3.35x | $-22.55 Million | $6.73 Million | ▼ -6.7% |
| 2020 | -3.14x | $-15.61 Million | $4.97 Million | ▼ -306.9% |
| 2019 | -0.77x | $-2.23 Million | $2.89 Million | ▼ -1890.6% |
| 2017 | -0.04x | $-724.43K | $18.69 Million | ▼ -48.6% |
| 2016 | -0.03x | $-509.16K | $19.52 Million | ▲ +90.1% |
| 2015 | -0.26x | $-5.36 Million | $20.45 Million | ▼ -1.8% |
| 2015 | -0.26x | $-5.36 Million | $20.82 Million | ▲ +15.7% |
| 2013 | -0.31x | $-2.70 Million | $8.85 Million | ▼ -13.0% |
| 2012 | -0.27x | $-1.04 Million | $3.86 Million | ▼ -47264.5% |
| 2011 | 0.00x | $-760.31K | $1.33 Billion | ▲ +99.9% |
| 2009 | -0.87x | $-636.48K | $735.65K | — |